Pneumonia Severity Index (PSI/PORT)
Predicts 30-day mortality in community-acquired pneumonia. Simplified from the full Fine/PORT score.
Score interpretation
PSI Class I–II (age ≤50 + no comorbidities, or score ≤70): 30-day mortality 0.1–0.7%. Note: Class I is assigned clinically (age ≤50, no comorbidities).
→ Outpatient treatment appropriate for most patients.
PSI Class III (score 51–90): 30-day mortality ~2.8%. Low-moderate risk.
→ Brief inpatient observation or outpatient treatment. Clinical judgement required.
PSI Class IV (score 91–130): 30-day mortality ~8.2%. Moderate risk.
→ Inpatient treatment recommended.
PSI Class V (score > 130): 30-day mortality ~29.2%. High risk.
→ Inpatient treatment. Consider ICU if sepsis criteria met or deteriorating.
Interpretation bands for the PSI/PORT. Apply clinical judgement and local guidance.
References
- Fine MJ et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997.
Related
Curated clinical cross-links plus same-class fallbacks.
- CRB-65 Score for Community Pneumonia · Pneumonia
- SMART-COP Score for Pneumonia Severity · Pneumonia
- CURB-65 Score for Community-Acquired Pneumonia · Pneumonia
- MuLBSTA Score for Viral Pneumonia Mortality · Pneumonia
- DRIP Score for Drug-Resistant Pneumonia · Pneumonia
- SCAP Score for Severe Community-Acquired Pneumonia · Pneumonia
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.